REMS That Block Generics Are ‘Major’ Problem For FDA, Jenkins Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Chief of new drugs office notes unintended consequence of safety legislation is thwarting development of ANDAs and biosimilars.